RGEN
$111.43
Repligen
($2.09)
(1.84%)
RGEN
Earnings Whisper ®
N/A
3rd Quarter September 2025
Consensus:  $0.42
Revenue:  $179.07 Mil
Tuesday
Oct 28
7:30 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when RGEN reports earnings?
Beat
Meet
Miss

Where is RGEN's stock price going from here?
Up
Flat
Down
Stock chart of RGEN
Analysts
Summary of analysts' recommendations for RGEN
Score
Grade
Pivots
Resistance
$116.09
$115.04
$113.24

$112.19

Support
$110.39
$109.34
$107.54
Tweet
Growth
Description
Repligen Corporation is a leading provider of advanced bioprocessing technologies and solutions used by large biopharmaceutical companies and contract manufacturing organizations for manufacturing biologic drugs, such as monoclonal antibodies (mAbs) and gene therapies. Repligen earns revenues from the sale of several products, which can be categorized mainly under three segments, namely Filtration, Chromatography and Protein products. The chromatography products include OPUS and OPUS PD chromatography columns, chromatography resins and ELISA test kits. Filtration products consist of XCell Alternating Tangential Flow (ATF) Systems and consumables, KrosFlo filtration products and SIUS filtration products. Protein products comprise the Protein A ligands and cell culture growth factors.
Peers
BiogenAmgenGilead SciencesNeurocrine BiosciencesQiagen N.V.Bio-TechneBioCryst PharmaceuticalsStemNovavaxSangamo Therapeutics